Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.967 USD | -0.31% | -46.28% | -73.21% |
May. 30 | Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from S&P TMI Index | CI |
May. 27 | Finch Therapeutics Group, Inc.(OTCPK:FNCH) dropped from NASDAQ Composite Index | CI |
Financials (USD)
Sales 2022 | 861K | Sales 2023 | 107K | Capitalization | 5.8M |
---|---|---|---|---|---|
Net income 2022 | -115M | Net income 2023 | -74M | EV / Sales 2022 | 5.01 x |
Net cash position 2022 | 18.68M | Net Debt 2023 | 5M | EV / Sales 2023 | 101 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
-0.08
x | Employees | 1 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 46.52% |
1 day | -0.31% | ||
1 week | -46.28% | ||
1 month | -58.13% | ||
3 months | -64.45% | ||
6 months | -78.46% | ||
Current year | -73.21% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Blischak
CEO | Chief Executive Officer | - | 23-05-15 |
Lance Thibault
DFI | Director of Finance/CFO | 58 | 23-05-15 |
Sonia Timberlake
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Graf
CHM | Chairman | 52 | 21-04-22 |
Jeffery Smisek
BRD | Director/Board Member | 69 | 17-08-31 |
Chris Shumway
BRD | Director/Board Member | 58 | 20-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.967 | -0.31% | 24,275 |
24-05-30 | 0.97 | +10.21% | 24,377 |
24-05-29 | 0.8801 | -27.26% | 52,748 |
24-05-28 | 1.21 | -32.78% | 111,960 |
24-05-24 | 1.8 | -9.09% | 629,479 |
Delayed Quote OTC Markets, May 31, 2024 at 03:34 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-73.21% | 1.55M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- FNCH Stock